Line 119: | Line 119: | ||
</br><h3 style="padding-top:0px;">References</h3> | </br><h3 style="padding-top:0px;">References</h3> | ||
<div class="col-md-14 content" style="max-width:1000px;padding:10px 50px;"> | <div class="col-md-14 content" style="max-width:1000px;padding:10px 50px;"> | ||
− | + | ||
<ul> | <ul> | ||
− | <li> | + | <li>Bowler, P. G., B. I. Duerden, and David G. Armstrong. "Wound microbiology and associated approaches to wound management." Clinical microbiology reviews 14, no. 2 (2001): 244-269.</il> |
− | <li> | + | |
− | <li> | + | <li>Chen, Xiaoying, Jennica L. Zaro, and Wei-Chiang Shen. "Fusion protein linkers: property, design and functionality." Advanced drug delivery reviews65, no. 10 (2013): 1357-1369.</il> |
+ | |||
+ | <li>Cutting, Keith F., and Richard White. "Defined and refined: criteria for identifying wound infection revisited." Br J Community Nurs 9, no. 3 (2004): S6-15.</il> | ||
+ | |||
+ | <li>Fivenson, David P., Duyen T. Faria, Brian J. Nickoloff, Peter J. Poverini, Steven Kunkel, Marie Burdick, and Robert M. Strieter. "Chemokine and inflammatory cytokine changes during chronic wound healing." Wound Repair and Regeneration 5, no. 4 (1997): 310-322.</il> | ||
+ | |||
+ | <li>Goldman, Robert. "Growth factors and chronic wound healing: past, present, and future." Advances in skin & wound care 17, no. 1 (2004): 24-35.</il> | ||
+ | |||
+ | <li>Harley, Brendan A., Janet H. Leung, Emilio CCM Silva, and Lorna J. Gibson. "Mechanical characterization of collagen–glycosaminoglycan scaffolds." Acta biomaterialia 3, no. 4 (2007): 463-474.</il> | ||
+ | |||
+ | <li>Harley, Brendan AC, and Lorna J. Gibson. "In vivo and in vitro applications of collagen-GAG scaffolds." Chemical Engineering Journal 137, no. 1 (2008): 102-121.</il> | ||
+ | |||
+ | <li>Hortensius, Rebecca A., and Brendan AC Harley. "Naturally derived biomaterials for addressing inflammation in tissue regeneration."Experimental Biology and Medicine (2016): 1535370216648022.</il> | ||
+ | |||
+ | <li>Johnson, A. Wagoner, and Brendan Harley, eds. Mechanobiology of cell-cell and cell-matrix interactions. Springer Science & Business Media, 2011.</il> | ||
+ | |||
+ | <li>O'Brien, Fergal J., Brendan A. Harley, Mary A. Waller, Ioannis V. Yannas, Lorna J. Gibson, and Patrick J. Prendergast. "The effect of pore size on permeability and cell attachment in collagen scaffolds for tissue engineering."Technology and Health Care 15, no. 1 (2007): 3-17.</il> | ||
+ | |||
+ | <li>O’Brien, Fergal J., Brendan A. Harley, Ioannis V. Yannas, and Lorna Gibson. "Influence of freezing rate on pore structure in freeze-dried collagen-GAG scaffolds." Biomaterials 25, no. 6 (2004): 1077-1086.</il> | ||
+ | |||
+ | <li>Yager, Dorne R., Stephen M. Chen, Susan I. Ward, Oluyinka O. Olutoye, Robert F. Diegelmann, and I. Kelman Cohen. "Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors." Wound Repair and Regeneration 5, no. 1 (1997): 23-32.</il> | ||
+ | |||
+ | <li>Yannas, I. V., D. S. Tzeranis, B. A. Harley, and P. T. C. So. "Biologically active collagen-based scaffolds: advances in processing and characterization."Philosophical Transactions of the Royal Society of London A: Mathematical, Physical and Engineering Sciences 368, no. 1917 (2010): 2123-2139.</il> | ||
</ul> | </ul> | ||
+ | |||
</div> <!-- End of col-md-14 --> | </div> <!-- End of col-md-14 --> | ||
</br></br><div class="col-md-2"></div> | </br></br><div class="col-md-2"></div> |
Revision as of 02:49, 20 October 2016
Project Overview
In 2010 it was estimated that 6.5 million people in the United States alone suffered from chronic wounds, accruing an annual cost of approximately $2.5 billion. Furthermore, experts predict that the burden of chronic wounds will increase rapidly in the near future due to increasing medical costs, an aging population, and the emergence of antibiotic resistant bacteria. Chronic wounds are characterized by their inability to progress through an orderly set of stages within a time period of about three months. Wound healing progresses through four successive stages known as hemostasis, inflammation, proliferation and remodeling.Our Goals
We will use synthetic biology principles to help treat chronic wounds by targeting the overproduction of wound site protease.
- For Aim 1 we will genetically engineer E. coli to produce a protease inhibitor and platelet derived growth factor.
- For Aim 2 we will purify the protease inhibitor and platelet derived growth factor in a bioreactor.
- For Aim 3 we will design a collagen bandage that mimics the human extracellular matrix, and infuse it with purified protease inhibitor and platelet derived growth factor.
Aim 1
Content
Aim 2
Content
Aim 3
Content
Conclusion
Content